18 May 2017  
EMA/CHMP/269250/2017  
Committee for Medicinal Products for Human Use (CHMP) 
Summary of opinion1 (post authorisation) 
Izba 
travoprost 
On 18 May 2017, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion 
recommending a change to the terms of the marketing authorisation for the medicinal product Izba. The 
marketing authorisation holder for this medicinal product is Novartis Europharm Ltd. 
The CHMP adopted a new indication as follows: 
"Decrease of elevated intraocular pressure in paediatric patients aged 3 years to < 18 years with 
ocular hypertension or paediatric glaucoma." 
For information, the full indications for Izba will be as follows2: 
"Decrease of elevated intraocular pressure in adult patients with ocular hypertension or open-
angle glaucoma.  
Decrease of elevated intraocular pressure in paediatric patients aged 3 years to < 18 
years with ocular hypertension or paediatric glaucoma."  
Detailed recommendations for the use of this product will be described in the updated summary of 
product characteristics (SmPC), which will be published in the revised European public assessment report 
(EPAR), and will be available in all official European Union languages after a decision on this change to 
the marketing authorisation has been granted by the European Commission. 
1 Summaries of positive opinion are published without prejudice to the Commission decision, which will normally be issued 67 
days from adoption of the opinion 
2 New text in bold 
30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom 
Telephone  +44 (0)20 3660 6000  Facsimile +44 (0)20 3660 5520 
Send a question via our website www.ema.europa.eu/contact 
An agency of the European Union   
© European Medicines Agency, 2017. Reproduction is authorised provided the source is acknowledged. 
 
  
 
 
 
  
                                                
